Aclaris Therapeutics
ACRS
97 hedge funds and large institutions have $1.14B invested in Aclaris Therapeutics in 2021 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 26 reducing their positions, and 17 closing their positions.
454% more capital invested
Capital invested by funds: $207M → $1.14B (+$938M)
400% more funds holding in top 10
Funds holding in top 10: 3 → 15 (+12)
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
52% more call options, than puts
Call options by funds: $6.4M | Put options by funds: $4.21M
23% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 26
18% more funds holding
Funds holding: 82 → 97 (+15)
13.27% more ownership
Funds ownership: 74.4% → 87.68% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$47.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$39.1M |
| 3 |
VA
VR Adviser
New York
|
+$34.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$25.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$13.1M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$12.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.77M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$6.65M |
| 5 |
CC
Commodore Capital
New York
|
-$6.03M |
ACRS Hedge Fund Activity: Q1 2021 in Review
97 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2021, worth a combined $1.14B — up 454% from $207M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ACRS positions and 17 closed out — a net gain of 16 holders — while 32 added to existing stakes and 26 trimmed.
The largest buyer was Foresite Capital Management IV, adding an estimated $47.9M. The largest seller was Endurant Capital Management, cutting an estimated $13.1M.
- 97 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2021, up from 82 in Q4 2020.
- Funds reported $1.14B of Aclaris Therapeutics stock for Q1 2021, up 454% quarter-over-quarter.
- 33 funds opened new Aclaris Therapeutics positions in Q1 2021 and 17 closed out, a net change of +16 holders.
- The largest Aclaris Therapeutics buyer in Q1 2021 was Foresite Capital Management IV, an estimated $47.9M added.
- The largest Aclaris Therapeutics seller in Q1 2021 was Endurant Capital Management, an estimated $13.1M sold.
Based on aggregated 13F filings for Q1 2021.